EPCAM (Epithelial cell adhesion molecule)

This finding indicates that EpCAM protein is highly expressed on the surface of exosomes secreted from breast cancer cells, and the expression of EpCAM protein from different types of cancer cells are also varies. The developed method has important application potential in terms of exosome analysis, and is expected to provide a new technical platform for breast cancer screening and prognosis assessment.

Similarly, there was no effect of unglycosylated EpCAM on cell viability, migration, invasion, or homotypic adhesion, although we did observe slight increases in homotypic cell-cell adhesion in EpCAM overexpressing cells. These findings show that N-glycosylation has a significant impact on stability and subcellular localization of EpCAM, but not on several critical breast cancer cell properties important for cancer progression and metastasis in human triple-negative MDA-MB-468 breast cancer cells.

Unlike conventional markers that often reflect tumor-specific traits, this panel captures the mechanical and structural determinants of cell invasiveness. The robustness of these genes across diverse molecular assays and their alignment with core metastatic pathways underscore their translational relevance.

By unifying cell-type identification, gene expression reconstruction, and spatial mapping within a single interpretable framework, SHEST provides a synergistic and cost-efficient bridge between histopathology and spatial transcriptomics. This approach facilitates comprehensive tissue characterization and forms a foundation for precision oncology through spatially informed, cell-level insights into tumour-immune ecosystems.

Our integrative analysis provides a comprehensive molecular and cellular atlas of BE. These findings enhance current understanding of BE pathogenesis and offer clinically relevant candidates for early detection and targeted intervention.

[This retracts the article DOI: 10.3892/ol.2014.2140.].

Furthermore, we highlight the development of highly promising alumina- and silica-based platforms for drug delivery (e.g., chemotherapeutics, photosensitizers, or gene delivery agents) in cancer. Ultimately, by providing a comprehensive overview alongside a critical analysis, we demonstrate that such nanostructures represent promising platforms for potential clinical translation in cancer medicine, helping to mitigate the limitations of conventional cancer therapies.

Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible.

Functional studies established that E2F2 directly regulates FZD10 expression, activating the Wnt/β-catenin pathway to sustain the stem-like state. Collectively, we unveil the E2F2/FZD10 axis as a previously unrecognized molecular conduit through which environmental arsenic reprograms mammary epithelial cells toward a BCSCs-like phenotype, providing mechanistic insight into arsenic-associated breast cancer risk and revealing a potential target for preventive intervention.

EpCAM and RUVBL1 are promising diagnostic biomarkers for EC, linking sEV-mediated pathways to disease progression. These findings provide insights into EC pathogenesis and highlight potential therapeutic targets.

This hybrid feature selection framework applied to patient derived cell lines, effectively reduces dimensionality, enhances biomarker reliability, and uncovers biologically interpretable mRNA signatures associated with ovarian cancer, demonstrating potential for diagnostic and therapeutic applications.

P=N/A, N=77, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027